Want to join the conversation?
$ENDP 2Q15 Q&A: Gary Nachman from Goldman Sachs asked about BELBUCA on schedule III status? Rajiv said our discussions with FDA have been encouraging & constructive. As we get closer to an actual approval & labeling discussions, then we'll be in better situation in terms pricing & reimbursement. Now, it’s too early to comment on it at this point.
Visa ($V) set to release it earning after market close today. With new CEO resigning so close to the earnings, should we expect to see any surprises? Visa has been making strong moves with Visa Europe acquisition, partnership with PayPal and a 15% increase if quarterly dividends.
Kimberly Clark Corp ($KMB) has been in decline for most of the year, the stock has also not been getting any analyst love. Will today’s earnings break the trend? Revenue has been up and down in the last four quarters, let us see what this quarter brings.
$KMB down close to 4% after it misses on earnings and revenue. Forecasts are lower for the year.